21:12 , May 9, 2018 |  BC Innovations  |  Translation in Brief

The fate of NK cells

New research is elucidating the relationship between CAR-transfected NK cells’ differentiation states and their cancer-killing potential -- knowledge that Fate Therapeutics Inc. (NASDAQ:FATE) is leveraging for its own cell therapies. In a study published in...
19:10 , Mar 9, 2018 |  BC Week In Review  |  Company News

BMS, Innate say no plans to table lirilumab just yet

Innate Pharma S.A. (Euronext:IPH) confirmed that discussions with partner Bristol-Myers Squibb Co. (NYSE:BMY) remain ongoing regarding next steps for cancer compound lirilumab (BMS-986015, IPH2102). In November, Innate said efficacy data from a Phase I/II trial...
22:21 , Dec 1, 2017 |  BC Week In Review  |  Clinical News

Innate sees no development path for lirilumab combo therapies

Innate Pharma S.A. (Euronext:IPH) said efficacy data from a Phase I/II trial of lirilumab (BMS-986015, IPH2102) in combination with Opdivo nivolumab to treat head and neck cancers "did not provide clear evidence of benefit to...
22:01 , Apr 7, 2017 |  BioCentury  |  Finance

Combo quest

By leading Viracta Therapeutics Inc. ’s series B round and forging a partnership for its lead HDAC inhibitor last week, NantKwest Inc. (NASDAQ:NK) took another step toward bolstering its natural killer cell therapy arsenal. Wicklow...
20:42 , Feb 10, 2017 |  BC Week In Review  |  Clinical News

Lirilumab: Ph II EffiKIR data

Top-line data from the double-blind, French Phase II EffiKIR trial in about 150 elderly AML patients in first complete remission showed that maintenance treatment with 0.1 mg/kg lirilumab every 3 months and 1 mg/kg lirilumab...
16:44 , Feb 6, 2017 |  BC Extra  |  Clinical News

Innate's lirilumab fails Phase II AML trial

Innate Pharma S.A. (Euronext:IPH) lost EUR 2.05 (16%) to EUR 11.05 on Monday after it said lirilumab ( IPH2102 ) missed the primary endpoint in the Phase II EffiKIR trial to treat elderly patients with...
22:17 , Jan 12, 2017 |  BC Week In Review  |  Company News

Innate Pharma, Bristol-Myers deal

Innate received a $15 million milestone payment from Bristol-Myers under a 2011 deal granting BMS exclusive, worldwide rights to lirilumab, a human mAb against killer cell immunoglobulin-like receptors (KIR). Innate said the milestone was triggered...
20:30 , Nov 11, 2016 |  BC Week In Review  |  Clinical News

Lirilumab: Ph I/II CA223-001 data

Data from a cohort of 29 evaluable patients with advanced platinum-refractory squamous cell carcinoma of the head and neck (SCCHN) in the open-label, dose-escalation, international Phase I/II CA223-001 trial showed that IV lirilumab every 4...
00:16 , Nov 9, 2016 |  BC Extra  |  Clinical News

Lirilumab combo shows early promise in SCCHN

Innate Pharma S.A. (Euronext:IPH) reported preliminary data from a Phase I/II trial of lirilumab ( IPH2102 ) plus PD-1 inhibitor Opdivo nivolumab that suggest the combination may offer a clinical benefit in patients with advanced...
21:06 , Nov 5, 2016 |  BioCentury  |  Finance

Vive la biotech

The French biotech sector has historically lagged other European countries such as the U.K. and Germany in both financings and deals. But a fledgling group of public bellwethers and a crop of innovative private companies...